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CancerFollicular dendritic cell sarcoma (FDCS) is an extremely rare neoplasm derived from antigen-presenting cells. It
behaves as an intermediate grade sarcoma and has high risk of local recurrence andmay metastasize. We report
the case of a 39-year-old woman who presented with a left mammary mass, and underwent a left mastectomy
and axillary lymph node dissection. Histopathological studies were consistent with the diagnosis of FDCS and
high grade breast carcinoma, both tumors involving the breast and the axillary lymph nodes. Such association
has not been previously described and therefore, FDCSmight be considered in the differential diagnosis of breast
tumors. We also review the previous cases reported in the literature involving the breast.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dendritic cells are a heterogeneous group of nonlymphoid accessory
cells present in the B- and T-cell areas of peripheral lymphoid tissue and
are responsible for major histocompatibility complex restricted stimu-
lation of resting T cells [1,2]. Neoplasms derived from follicular dendritic
cells (FDCNs) are rare and usually occur within lymphoid tissue or
extranodal sites [3–6]. Extranodal involvement of FDCNs can be the pri-
mary presentation of the tumors or may occur during the course of the
disease. Breast involvement is very rare and, to date, no primary or sec-
ondary involvement of the breast by FDCNs, associated with invasive
carcinoma has been described. At this site the diagnosis of FDCNs is
challenging because they may mimic primary or metastatic neoplasms.
We report the ﬁrst case of FDC sarcoma (FDCS) associatedwith invasive
carcinoma presenting in the breast. We review and discuss the clinico-
pathological features of FDCS in this location.
2. Clinical summary
A39-year-oldwoman diagnosed of breast cancerwas referred to our
institution to complete treatment in June 2015. On physical examina-
tion, the patient had presented a left mammary tumor of 20 mm diam-
eter located in the junction of the external quadrants. Breast
ultrasonography study revealed a well-deﬁned 20 mm lesion in the
same site of left breast associated with enlarged left axillar lymphHospital Sant Joan de Reus, Av.
).
c. This is an open access article under
icular dendritic cell sarcoma anodes. A tru-cut of the breast lesionwas performed and leftmastectomy
with axillary lymphadenectomy was the ﬁnal surgical treatment
elected.
3. Pathological ﬁndings
On histological grounds, the features observed in both the breast
core tru-cut biopsy and the surgical specimen were similar (Figs. 1
and 2). Two atypical components that growth relatively separated by
a ﬁbrous pseudocapsule were identiﬁed. The major part of the lesion
was composed by a multinodular proliferation of medium-to-large
pleomorphic-shaped cells with an irregular syncytial growth pattern
and organized forming large nests. The neoplastic cells had large pale
cytoplasm and round-to-ovoid vesicular nuclei with irregular nuclear
membranes. Binucleated cells were frequent and the nucleoli were gen-
erally prominent. Themitotic ratewas 1–2mitoses per high-powerﬁeld
and abnormal mitotic ﬁgures were frequent. Myxoid areas and necrosis
were absent. Small lymphocytes and plasma cells were commonly iden-
tiﬁed within the cytoplasm of individual atypical cells and surrounded
the nests as well. Eosinophils were absent. An additional focus of large
and atypical cells with eosinophilic cytoplasm and vesicular nuclei
was observed. In this area the cells tended to grow more isolated or
formed small groups of ﬁve to ten cells and were surrounded by
desmoplastic stroma and an inﬂammatory component mainly com-
posed by mature plasma cells. This area represented 5 to 10% of the
total tumoral component.
The immunohistochemical studies allowed differentiating both
components. Cytokeratins AE1/AE3, 5/6, 7, 19 and CAM 5.2 highlighted
the cells of the minor component, which were negative for thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Breast biopsy ﬁndings. a–c Histological features (a). The tumor had amultinodular appearancewith ﬁbrous septa (b,c). The nodules showed atypical polygonal or oval cells with ill-
deﬁned cell borders, eosinophylic cytoplasm, and oval or convoluted nuclei. They are admixed with small lymphocytes and plasma cells and a few bizarre, multinucleated giant cells. d–f
Examples of immunohistochemical features (d,f). The neoplastic cells were not reactive to cytokeratin AE1/AE3 (e,f). The neoplastic cells showed isolated immunoreactive for CD20 and
CD15.
2 D. Parada et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxhormonal receptors and HER2. The predominant component of the
tumor did not express cytokeratins and the neoplastic cells had strong
expression of vimentin, CD21 and CD15, and focal expression of EMA,
CD23 and p63. Lymphoid markers such as CD45, PAX5, CD20, CD79a,
CD3, CD5, CD7, CD4, CD8, CD30, ALK-1, CD68, smooth muscle actin, S-
100 protein, melan-A or HMB45. The accompanying lymphocytes
were predominantly CD4 in the major component, and were less fre-
quent in theminor component, whichwas enriched in polytypic plasma
cells. The axillary lymph node dissection obtained 34 lymph nodes and
revealed metastasis of carcinoma in 2 lymph nodes and follicular den-
dritic cell sarcoma in 4 (Fig. 3). Notably, both tumors were admixed
and involved one lymph nodes. In situ hybridization for the mRNA of
the genes EBER-1 and 2 of the EBV was negative in our case, and no ev-
idence of Castleman disease was identiﬁed in the breast or axillary
lymph nodes. The ﬁnal diagnosiswas triple negative invasive carcinoma
of no special type (pT1a) with axillary lymph node metastases pN1a (2
positive lymph nodes), associated with FDCS involving simultaneously
the breast and the axillary lymph nodes. The presence of BRAF V600E
mutation was examined by Sanger sequencing and was absent in both
sarcoma and carcinoma components.
Further imaging studies and exploration of the head and neck area
did not ﬁnd evidence of additional disease. The patient received four cy-
cles of chemotherapy with doxorubicin, cyclophosphamida, andPlease cite this article as: D. Parada, et al., Follicular dendritic cell sarcoma a
http://dx.doi.org/10.1016/j.ehpc.2016.10.002paclitaxel. The patient will receive adjuvant radiotherapy and after six
months of follow-up is free from disease.
4. Discussion
Dendritic cells are professional antigen presenting cells that partici-
pate in both innate and adaptive immune response [1,2]. They are a het-
erogeneous group of cells that includes Langerhans' cells, dermal
dendrocytes, follicular dendritic cells, and interdigitating dendritic
cells. Tumors arising from dendritic cells, such as FDCS and interdigitat-
ing dendritic cell sarcoma (IDCS) are very rare [3–7]. About 400 cases of
FDCS have been reported in the English literature [3,6]. FDCS occurs at
an average age of 50 but can range between 9 and 90 years old, and
have no gender predominance. FDCS behaves like an intermediate
grade sarcoma with a substantial risk of local recurrence (28.1%) and
distant metastasis (27.2%) [3].
Tumorsmay occur at both nodal and extranodal locations as isolated
disease in 31% and 58% of cases, respectively [3]. The oropharynx,
parapharyngeal space, neck tissues, and tonsil are the most common
extranodal sites involved, and in approximately 8–10% of cases can be
simultaneously involved with cervical lymph nodes [3,6]. Additional
extranodal sites have been described in the lungs, spleen, liver, gastroin-
testinal tract, pancreas and axial skeleton, associated or not withnd invasive carcinoma of the breast, Human Path Case Reports (2016),
Fig. 2.Breast tumorectomy ﬁndings. a–c Histological features (a). The tumor had amultinodular appearance andwas demarcated by the adjacent breast parenchyma (b). On the periphery
an in-situ carcinoma can be observed (c). The nodules showed atypical cells with characteristics similar to those described in Fig. 1 d–f. Examples of immunohistochemical features (d,e).
The neoplastic cells were reactive to vimentin and p63 (e). Reactivity for cytokeratin AE1/AE3 was present in a minimal focus of carcinoma.
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ports of FDCS involving the breast, any of them presenting with simul-
taneous breast carcinoma [8–10]. Table 1 shows the clinical features of
these cases, including our case. The mean age of the patients was
38 years, three cases occurred in the left breast, and the size of the tu-
mors ranged from 20 to 50 cm (mean 34 mm). Histologically, the tu-
mors had heterogeneous features, and showed mixed diffuse,
fascicular and myxoid patterns of growth. The tumors were resected
in all patients and one received radiotherapy 6 months after relapse of
the disease, but chemotherapy was not elected for the treatment in
the previous cases. After a follow-up ranging from 6 months to
3 years, all patients were alivewith no evidence of FDCS. Two additional
cases describe the involvement of the breast by IDCS. Such cases had
variable biological behavior, and one patient was alive without disease
at 32months of follow-up, and the second died of pulmonary embolism
3 weeks after surgery [10,11].
Extranodal FDCS is a challenging diagnosis, particularly those cases
occurring outside the upper respiratory tract, which is more frequently
involved. The histological features of the tumors may include fusiform
and polygonal-shaped large cells with frequent binucleated nuclei, as-
sociatedwith small lymphocytes, whichmay be helpful to raise the sus-
picion of the disease. The immunohistochemical proﬁle of FDCS shows
the expression of at least one FDCmarker, and many cases may express
two or more FDCmarkers. The neoplastic cells can occasionally expressPlease cite this article as: D. Parada, et al., Follicular dendritic cell sarcoma a
http://dx.doi.org/10.1016/j.ehpc.2016.10.002EMA, histiocytic markers and S100 protein [7,12]. Contrary to the re-
ported cases of FDCS involving the breast, our case did not express S-
100 protein [8–10]. The coexistence of triple negative carcinoma
added difﬁculty in the diagnosis of FDCS, and we considered the possi-
bility ofmedullary carcinoma,metaplastic and undifferentiated carcino-
mas in the differential diagnosis, in addition to malignant melanoma,
sarcomas of different derivations and hematological tumors composed
by large cells either of B or T-cell origin.
BRAF V600E mutations have been described in tumors of dendritic
and histiocytic derivation, particularly histiocytic sarcoma and
Langerhans cells tumors. Among dendritic cell tumors, 3/22 (14%)
FDCS and 2/5 (40%) inﬂammatory pseudotumor-like variant of FDCS
presented BRAF V600E mutation studied by Sanger sequencing and by
qPCR [13]. Two additional studies did not identify BRAF V600Emutation
in a total number of 9 cases of FDCS studied by immunohistochemistry
with speciﬁc antibodies or molecular methods [14,15].
In summary, we describe a case of a FDCS involving the breast and
we have reviewed the clinicopathological features of such uncommon
presentation. Of note, to the best of our knowledge the association of
FDCS and simultaneous carcinoma has not been reported yet.
Compliance with ethical standards
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Fig. 3.Axillary lymphnode ﬁndings. a,b Histological features (a,b). The tumor showed two aspects (a) diffuse and (b) sinusoidal. c–h Examples of the immunohistochemical features (c,e).
The epithelial neoplastic cells were reactive to cytokeratin AE1/AE3. Intermixed atypical cells of FDCS were negative (d,f,g,h). FDCS cells were reactive to EMA, CD15, Fascin and p63.
Table 1
Summary of extranodal follicular dendritic cell sarcomas reported in the breast.
Reference Age/site Size Treatment Follow-up (months)
Fisher et al. 41/left 25 mm Quadrantectomy; mastectomy, RT Relapse after 6 months, ANED 36
Pruneri et al. 40/right 40 mm Quadrantectomy, sentinel lymph node biopsy ANED, 19
Kapucuoglu et al. 31/left 50 × 40 mm Radical mastectomy ANED, 13
Present case 39/left 20 mm Mastectomy, axillar lymphadenectomy, CT ANED, 6
RT, radiotherapy; CT, chemotherapy; ANED, alive with no evidence of disease.
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